Related Experiment Videos
Pharmacogenomics of statin response
Lara M Mangravite1, Ronald M Krauss
1Children's Hospital Oakland Research Institute, Oakland, California 94609, USA.
Current Opinion in Lipidology
|July 11, 2007
Summary
Genetic variations influence how well statins work, but current findings explain only a small part of the differences. Future research aims to identify more genetic markers for better prediction of statin response and cardiovascular disease risk.
Area of Science:
- Pharmacogenomics
- Cardiovascular Disease Research
Background:
- Statin therapy significantly reduces cardiovascular disease (CVD) risk.
- Wide inter-individual variability exists in statin efficacy and clinical outcomes.
Purpose of the Study:
- Investigate genetic factors influencing statin efficacy.
- Explore the link between genetic polymorphisms and statin response.
- Identify genetic markers for predicting statin efficacy and toxicity.
Main Methods:
- Review of studies on gene polymorphisms affecting statin pharmacodynamics and pharmacokinetics.
- Discussion of genome-wide association studies (GWAS) for marker discovery.
Main Results:
- Known gene polymorphisms explain only a small portion of statin efficacy variation.
- GWAS show promise for identifying comprehensive markers for statin response and muscle toxicity.
Conclusions:
- Replication of findings in diverse populations is crucial for clinical applicability.
- Connecting biomarker effects to clinical outcomes and individual statin effects is necessary.
- Discovering specific genotypes and their functional effects can improve understanding of CVD risk and identify new therapeutic targets.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...